FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of $104.45 million. The enterprise value is $129.02 million.
| Market Cap | 104.45M |
| Enterprise Value | 129.02M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 99.48 million shares outstanding. The number of shares has increased by 4.53% in one year.
| Shares Outstanding | 99.48M |
| Shares Change (YoY) | +4.53% |
| Shares Change (QoQ) | +0.48% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 61.62% |
| Float | 90.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 61.35 |
| PS Ratio | 0.62 |
| Forward PS | 0.76 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41
| Current Ratio | 1.41 |
| Quick Ratio | 1.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -54.50% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $344,636 |
| Profits Per Employee | -$494,774 |
| Employee Count | 486 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | -38,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.88% in the last 52 weeks. The beta is 0.71, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -55.88% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 52.18 |
| Average Volume (20 Days) | 2,529,858 |
Short Selling Information
The latest short interest is 7.32 million, so 7.36% of the outstanding shares have been sold short.
| Short Interest | 7.32M |
| Short Previous Month | 8.09M |
| Short % of Shares Out | 7.36% |
| Short % of Float | 8.08% |
| Short Ratio (days to cover) | 2.73 |
Income Statement
In the last 12 months, FibroGen had revenue of $167.49 million and -$240.46 million in losses. Loss per share was -$2.45.
| Revenue | 167.49M |
| Gross Profit | 126.38M |
| Operating Income | -236.79M |
| Pretax Income | -240.50M |
| Net Income | -240.46M |
| EBITDA | -214.56M |
| EBIT | -222.34M |
| Loss Per Share | -$2.45 |
Balance Sheet
The company has $177.60 million in cash and $202.17 million in debt, giving a net cash position of -$24.57 million or -$0.25 per share.
| Cash & Cash Equivalents | 177.60M |
| Total Debt | 202.17M |
| Net Cash | -24.57M |
| Net Cash Per Share | -$0.25 |
| Equity (Book Value) | -228.12M |
| Book Value Per Share | -2.29 |
| Working Capital | 81.43M |
Cash Flow
In the last 12 months, operating cash flow was -$272.72 million and capital expenditures -$1.96 million, giving a free cash flow of -$274.68 million.
| Operating Cash Flow | -272.72M |
| Capital Expenditures | -1.96M |
| Free Cash Flow | -274.68M |
| FCF Per Share | -$2.78 |
Margins
Gross margin is 75.46%, with operating and profit margins of -141.37% and -143.56%.
| Gross Margin | 75.46% |
| Operating Margin | -141.37% |
| Pretax Margin | -143.59% |
| Profit Margin | -143.56% |
| EBITDA Margin | -128.10% |
| EBIT Margin | -132.75% |
| FCF Margin | -163.99% |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.53% |
| Shareholder Yield | -4.53% |
| Earnings Yield | -230.22% |
| FCF Yield | -262.97% |
Analyst Forecast
The average price target for FibroGen is $2.00, which is 90.48% higher than the current price. The consensus rating is "Sell".
| Price Target | $2.00 |
| Price Target Difference | 90.48% |
| Analyst Consensus | Sell |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FibroGen has an Altman Z-Score of -8.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.34 |
| Piotroski F-Score | 1 |